Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Remimazolam vs Etomidate for ECT Induction
NCT06664138Phase 4Completed
- Start
- Apr 2023
- Primary completion
- Jan 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of remimazolam in major depressive disorder (MDD), schizophrenia, schizoaffective disorder. Started Apr 2023; status: completed.
02
Drugs
remimazolam
03
Conditions
major depressive disorder (MDD)schizophreniaschizoaffective disorder
Beyond the preview
Go deeper on NCT06664138.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06664138.